TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03049033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurologic Music Therapy
Description: Neurologic Music Therapy uses rhythms to change brain activity and function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: Occupational Therapy uses traditional motor training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Supported Therapy
Description: Music Supported Therapy uses musical instruments to train fine motor movements.
Study: NCT02456311

Intervention type: DEVICE
Group type: OTHER
Intervention: HARMONIC ACE+7
Description: Pulmonary artery sealing with Harmonic Ace+7 in open lobectomy in humans
Study: NCT05054634

Intervention type: BEHAVIORAL
Intervention: Psycho-oncological Intervention Based on Counselling (PIBC)
Description: Patients in EG received a psycho-oncological intervention based on Counselling (PIBC) following the scheme proposed by Arranz and Cancio in addition to the standard treatment. The evolution of anxiety and depression was evaluated using Hospital Anxiety and Depression Scale (HADS). The aim of the study was to evaluate the effectiveness of a PIBC in reducing anxiety and depression of patients with DTC. Other QoL relevant items were also evaluated using the Short Form-36 Health Survey (SF-36) and Psychological General Well-Being Index (PGWBI) scales.
Study: NCT00510237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescents Coping, Connecting, Empowering, and Protecting Together (Project ACCEPT)
Description: The intervention will consist of a combination of individual and group-based sessions in which the youth will participate. This combination allows for more intensive individualized attention as well as supportive group sessions. Youth will first participate in two individual sessions, followed by nine group sessions, and end with one additional individual session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescents Coping, Connecting, Empowering, and Protecting Together (Project ACCEPT)
Description: The intervention will consist of a combination of individual and group-based sessions in which the youth will participate. This combination allows for more intensive individualized attention as well as supportive group sessions. Youth will first participate in two individual sessions, followed by nine group sessions, and end with one additional individual session.
Study: NCT03638973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser or scalpel under previous local anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser or scalpel under previous local anesthesia.
Study: NCT01557114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Induction: Treatment with ipilimumab will be administered on weeks 1, 4, 7 and 10 at 10mg/kg.~Maintenance: Ipilimumab will be administered intravenously over 90-minutes at 10 mg/kg every 12 weeks starting at week 24, for as long as the treating physician believes that there is a clinical benefit or for as long as patient is tolerant of therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation therapy 9 Grays in 3 Grays fractions Radiation therapy 15 Grays in 5 Grays fractions Radiation therapy 18 Grays in 6 Grays fractions Radiation therapy 24 Grays in 8 Grays fractions
Study: NCT04737187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine/Tipiracil
Description: Taken by mouth two times a day, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: Taken by mouth two times a day, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: administered every 2 weeks (Day 1 and Day 15)
Study: NCT02280694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Study: NCT02865226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: paravertebral block by the anesthetist before incision (paravertebral block guided by ultrasound)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block by the thoracic surgeon at chest closure (paravertebral block visual).
Study: NCT02166112

Intervention type: PROCEDURE
Intervention: Permacol mesh placement
Description: All patients were treated for a complex abdominal wall hernia by implantation of Permacol mesh. This intervention took place before patients were included in the cohort.
Study: NCT00963053

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VA111913 TS and placebo
Description: VA111913 TS twice daily for a maximum of 6 days during one menstrual cycle followed by placebo twice daily for up to a maximum of 6 days during a second menstrual cycle in a cross over design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA111913 TS and placebo
Description: VA111913 TS twice daily for a maximum of 6 days during one menstrual cycle followed by placebo twice daily for up to a maximum of 6 days during a second menstrual cycle in a cross over design
Study: NCT03183726

Intervention type: BIOLOGICAL
Intervention: ALLO-ASC-DFU
Description: ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide an new option in treating a diabetic foot ulcer.~This study is a follow-up study without intervention.
Study: NCT03707002

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: scFOS
Description: daily intake for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: daily intake for 6 weeks
Study: NCT00026130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 200mg/sq m/d CIVI 5/7 days during radiation therapy (wks 1-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 200mg/sq m IV infusion over 30 min wkly (on d 1, 2, OR 3) during radiation tx (wks 1-6) 1000mg/sq m IV infusion over 30 min wkly for 3 weeks during ea chemotherapy cycle

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 4500cGy total in 25 fractions M-F followed by 540cGy in 3 fractions (Total dose 5040cGy)during radiation tx (wks 1-6)
Study: NCT02097940

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: proprioceptive exercises
Description: Exercises with movements, jumping and imbalance.
Study: NCT05222867

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lower back massage
Description: Lower back massage performance: In the study, Linda Kimber's massage protocol was used. First, the researcher ensured that the patient was holding the bed, squatting, or bent over on the bed, which is suitable for the massage, between two contractions. The pregnant woman was instructed to breathe deeply and exhale audibly when her contractions began. Gloves were worn during the massage and liquid Vaseline, which does not contain any active substance, was used to provide lubricity. The circular hip massage was applied at the beginning of the contraction, and lower lateral area and sacral pressure massage was applied towards the end of the contraction as per the massage protocol, and simultaneously with the inhaling sound of the pregnant woman
Study: NCT04096690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Pegaspargase 3750IU administered by intramuscular injection on Day 1 of each 21-day cycle for 6 cycles in induction treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 2 of each 21-day cycle for 6 cycles in induction treatment Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 1 of each 21-day cycle for up to 28 cycles in maintenance treatment
Study: NCT00372645

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid (supplement)
Description: 200 µg folate per day from supplemental folic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metafolin (supplement)
Description: 200 µg folate per day from supplemental Metafolin®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04183101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Patients will be randomized to start treatment with aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight. After 6 months switch to enalapril 2.5-20 mg daily and continue with that 2.5 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Patients will be randomized to start with enalapril 2.5-20 mg daily depending on weight. After 6 months switch to aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight and continue with this treatment for 2.5 years.
Study: NCT00372645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Folate rich foods
Description: 200 µg folate per day from folate-rich foods
Study: NCT06071559

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Roux-en-y gastric bypass
Description: Obesity surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Roux-en-y gastric bypass
Description: Obesity surgery
Study: NCT01279213

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paliperidone clozapine
Description: dose 3 to 12 mg paliperidone ER daily during 12 weeks
Study: NCT01080261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMUS Element
Description: PROMUS Element Everolimus-Eluting Coronary Stent System
Study: NCT01279213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paliperidone clozapine
Description: dose 3 to 12 mg paliperidone ER daily during 12 weeks
Study: NCT01459900

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal artery ablation
Description: Catheter based renal denervation by applying low power radiofrequency to the renal artery using the Ardian Medtronic Simplicity Catheter, introduced by femoral artery access.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Renal angiography
Description: Renal angiography by femoral access.
Study: NCT00350233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 2000
Study: NCT01910181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Participants will receive vemurafenib at a dose of 960 mg twice daily orally.
Study: NCT04141605

Intervention type: DEVICE
Intervention: SherpaPak Cardiac Transport System
Description: The Paragonix SherpaPak Cardiac Transport System (SherpaPak CTS) is an ultraportable hypothermic preservation and transport system intended for use with donor hearts. The device is a legally marketed, FDA cleared medical device in the United States and CE Marked medical device in the European Union.~The SherpaPak CTS consists of multiple components: 1) outer transport shipper which contains within various non-ice based temperature controlled packaging elements, 2) an inner and outer hard shell assembly which provides a rigid barrier enclosure in which the heart is immersed and suspended in a cold storage solution cleared for use in storing and transporting donor hearts, 3) a data logger that monitors and displays the temperature of the cold storage solution in which the heart is stored during transport, and 4) four size heart connectors designed to accommodate various size aortic stem diameters by which donor hearts are attached.
Study: NCT03409627

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INXN-4001
Description: Retrograde coronary sinus infusion of triple effector plasmid (INXN-4001)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INXN-4001
Description: Retrograde coronary sinus infusion of triple effector plasmid (INXN-4001)
Study: NCT00744341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV320
Description: 1.25mg i.v. bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV320
Description: 3.75mg i.v. bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV320
Description: 7.5mg i.v. bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV320
Description: 15.0mg i.v. bid
Study: NCT03319849

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NT-501
Description: Each NT-501 implant consisted of hCNTF-secreting NTC-201-6A.02 cells encapsulated within supportive matrices and surrounded by a semipermeable polymer membrane.~The NTC-201-6A cells continuously secrete CNTF from the NT-501 implant into the vitreous cavity. Implanted by a qualified Health Care Professional.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham surgery involved a superficial conjunctival incision performed under local anesthetic and closure with a single suture.
Study: NCT00744341

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01922999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: patients will receive placebo, 1mg melatonin or 3mg melatonin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: patients will receive placebo, 1mg melatonin or 3mg melatonin
Study: NCT01865851

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classic Face Mask and NuMask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classic Face Mask and NuMask
Study: NCT01715246

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant Formula

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Infant Formula
Study: NCT01125930

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle gel
Description: Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atralin gel
Description: Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
Study: NCT03627676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Two percutaneous cryoprobes would be used for all patients. The 17-Gauge cryoprobes is introduced into the masses under US guidance. Mean distance to the skin has to be 5mm at least. Although US guidance is used, a non-enhanced CT scan may be used to assess the position of the cryoprobes before ablation, and to obtain a baseline examination in order to avoid thermal injuries to adjacent tissues such as the bowel during the ice growth. No ice extension to the skin has to be observed during cycles assessed by real-time US monitoring. Each cryoablation procedure involves 3 successive cycles: 10 minutes freeze with Argon gas, followed by 9 minutes passive and 1 minute active thawing with Helium gas, followed by a second 7 minutes freeze. The ice covered the entire targeted lesion on the short axes is visualize by US or CT-scan performed at the end of the three cycles or after repositioning. At the end of the cryoablation procedures, the probes are removed through active thawing.
Study: NCT05105685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone
Description: RhGH treatment was started at 0.1 IU/kg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline was started at 0.1 IU/kg once daily as the placebo
Study: NCT03981861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Spironolactone
Description: Oral Metformin tablet (500 mg/tablet) twice daily for 6 months. Oral Spironolactone tablet (50 mg/tablet) once daily for 6 months.
Study: NCT06611189

Intervention type: OTHER
Intervention: surgery
Description: In order to preserve kidney from warm ischemia during graft implantation, on the back table, graft were prepared for implantation with standard techniques. The kidney was introduced into the bag which was filled with a small amount of ice and preservation fluid (Figure 1). After inplacement of the graft, a small hole was made near the hilum and the renal artery and vein were passed through the hole. A Kocher clamp was used to maintain the fluid and ice in place and as a handle. Also, a Hartman Mosquito Clamp was used to mark urether-side, and to maintain orientation.

Intervention type: OTHER
Intervention: Ray-Tech sponge technique
Description: On the back table, graft were prepared for implantation with standard techniques. A Raytech sponge is soaked in ice-cold preservative solution, and wrapped around the kidney and held with a clamp (Figure 2). Position and oriantation of the graft was done by direct vision of urether.
Study: NCT01307579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin Acetate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Given IV or PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02871258

Intervention type: DEVICE
Group type: OTHER
Intervention: The MetaNeb® System
Study: NCT02934685

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofraction
Description: 70 Gy in 28 fractions over 5.6 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: convention
Description: 80Gy in 40 fractions over 8 weeks
Study: NCT02367560

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needle decompression
Description: Direct manipulation of calcium deposits in the shoulder with a needle to fragment the deposit performed by a radiologist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shockwave therapy
Description: A physiotherapist performs the shockwave therapy procedure. Treatment is completed in 4 weekly sessions. Treatment involves applying soundwaves directly to the affected shoulder area using an ultrasound device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo medrol
Description: Subacromial steroid injection (40 mg depo medrol) is given to the patient to limit irritation following needle decompression.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound device
Description: Ultrasound device is applied directly to the shoulder at 0.2 mJ/mm2.
Study: NCT03163628

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diagnostic performances of a combination of biomarkers
Description: 3 ml of blood will be drawn at inclusion at the same time of the venipuncture prescribed for standard care. The dosage of the 7 biomarkers will be performed in a central laboratory. The adjudication committee will classify patients in 6 groups, based on their clinical data. The committee will not be aware of the biological results. The analysis of Train Set data will aim to identify the most effective combination of markers in response to the primary objective of identifying biomarkers for the diagnosis of severe bacterial infections. The best combination selected will then be applied to the Test Set data (approximately the other half of patients), in order to obtain its real and unbiased performance.~The calculation of positive and negative likelihood ratios will be performed.~The targeted performances are:~* A positive likelihood ratio (LR +) of 5.67 minimum, ideally greater than 8.5.~* A negative likelihood ratio (LR-) of 0.5 maximum, ideally less than 0.3.
Study: NCT02369653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No systemic anticoagulant prophylaxis
Study: NCT04087447

Intervention type: PROCEDURE
Intervention: Thyroidectomy
Description: Thyroidectomy
Study: NCT00666250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xocai Activ drink
Description: proprietary blend of cocoa powder and extracts of acai, grape and blueberry

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xocai Activ drink
Description: proprietary blend of cocoa powder and extracts of acai, grape and blueberry
Study: NCT02186041

Intervention type: DEVICE
Intervention: Sacral Nerve Modulation

Intervention type: DEVICE
Intervention: Sacral Nerve Modulation

Intervention type: DEVICE
Intervention: Sacral Nerve Modulation
Study: NCT03483428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventionist training and supervision
Description: Online and in-person training and weekly supervision with licensed clinical social worker while delivering the Family Check-Up to 5 families.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral parent training
Description: Up to 6 sessions of the Family Check-Up program, involving discussions, assessments, feedback, and skills training with a parent coach.
Study: NCT04301050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: Weekly 75-minute yoga classes.
Study: NCT00095329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sirolimus
Study: NCT00779337

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous AdE1- Latent Membrane Protein CTLs
Description: Total dose 20-800 million CTL given in 4 equal doses (5-200 million CTL) given intravenously, at weekly intervals for the first cohort of 10 patients and twice a week for the second cohort of 10 patients.